07:00 , May 21, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Apolipoprotein C-III (APOCIII; APOC3)

Endocrine/metabolic disease INDICATION: Diabetes In vitro and mouse studies suggest depleting APOCIII in islets could help treat diabetes. Levels of APOCIII mRNA were higher in islets from a mouse model of obesity-induced diabetes than in islets from...
07:00 , Apr 9, 2015 |  BC Innovations  |  Translation in Brief

Super-additive silencing

Tekmira Pharmaceuticals Corp. has a dual-targeting RNAi that could treat hypertriglyceridemia more effectively than therapeutics that silence either target alone. The two-component product, TKM-HTG, contains RNAi components that separately target apolipoprotein C-III (APOC3; APOCIII) and angiopoietin-like...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Alnylam pharmaceuticals news

Alnylam outlined plans to focus its RNAi pipeline on genetic medicine, cardio-metabolic diseases and hepatic infectious diseases. Clinical genetic medicine programs include Phase III transthyretin-mediated amyloidosis (ATTR) candidates patisiran and revusiran as well as...